← Leaderboards
David P Kelsen
Sloan-Kettering Institute For Cancer Res
$4,038,621
Attributed
$4,038,621
Total exposure
3
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $3.1M · FY2006–11$5M$3.8M$2.5M$1.3M$0
'06
'07
'08
'09
'10
'11
Funding mix
By agency
NIH$4,038,621 · 3
By mechanism
N01$3,803,106 · 2
U01$235,515 · 1
Top collaborators
No co-investigators on record.
Most similar at Sloan-Kettering Institute For Cancer Res
Same institution · by research overlap
- Pier Paolo Pandolfi$54,825,346
- Alan N. Houghton$9,129,158
- David R Spriggs$13,987,182
- Riccardo Dalla-Favera$29,692,137
- Joseph Rocco Bertino$26,398,552
Others in their field
Top investigators on “Clinical Trials”
- Lawrence Corey · Fred Hutchinson Cancer Center$824,102,536
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Heimbrook · Leidos Biomedical Research, Inc.$622,583,125
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$542,008,718
- Bambra Strokes · Ppd Development Lp$526,656,217
- Judith S. Currier · University Of California Los Angeles$504,273,077
Research focus
Clinical TrialsNew AgentsContractsMalignant NeoplasmsNational Cancer InstituteCancer Therapy Evaluation ProgramClinically RelevantBloodEthnic GroupImage AnalysisBaseCombined Modality TherapyConduct Clinical TrialsContractorElderlyData ReportingMolecular TargetDevelopment PlansAntitumor AgentDoseEvaluation ResearchDrug DevelopmentDrug KineticsOrgan
Grant awards (6)
Early Therapeutics Development with Phase II Emphasis$377,050
N01 · FY2011 · CA · contact PI
Early Therapeutics Development with Phase II Emphasis$346,045
N01 · FY2010 · CA · contact PI
TAS:: 75 0850 ::TAS RECOVERY ACT - ACTNOW CLINICAL TRIAL 8461$2,227,911
N01 · FY2009 · CA · contact PI
Early Therapeutics Development with Phase II Emphasis$852,100
N01 · FY2009 · CA · contact PI
EARLY THERAPEUTICS DEVELOPMENT WITH PHASE II EMPHASIS-261622006$0
N01 · FY2006 · CM · contact PI
PHASE II/III CLINICAL TRIALS OF ANTICANCER AGENTS$235,515
U01 · FY2000 · CA